Antares Pharma (NASDAQ:ATRS) Rating Increased to Hold at Zacks Investment Research – MarketBeat

Antares Pharma (NASDAQ:ATRS) was upgraded by Zacks Investment Research from a "sell" rating to a "hold" rating in a research note issued to investors on Tuesday, Zacks.com reports.

According to Zacks, "Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. "

Other analysts also recently issued reports about the company. LADENBURG THALM/SH SH restated a "buy" rating and issued a $7.00 price objective on shares of Antares Pharma in a report on Sunday, June 21st. HC Wainwright decreased their price objective on Antares Pharma from $5.00 to $4.50 and set a "buy" rating for the company in a report on Wednesday, May 6th. BidaskClub upgraded Antares Pharma from a "sell" rating to a "hold" rating in a report on Thursday, April 30th. Finally, Piper Sandler restated an "overweight" rating and issued a $5.00 price objective on shares of Antares Pharma in a report on Sunday, June 21st. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Antares Pharma has a consensus rating of "Buy" and a consensus target price of $5.63.

Shares of NASDAQ:ATRS traded down $0.10 during trading on Tuesday, hitting $2.70. 771,469 shares of the company were exchanged, compared to its average volume of 1,483,594. The business's 50 day moving average is $2.84 and its 200-day moving average is $3.23. The company has a market capitalization of $462.74 million, a P/E ratio of 135.07 and a beta of 1.36. The company has a quick ratio of 2.55, a current ratio of 3.01 and a debt-to-equity ratio of 0.85. Antares Pharma has a 1-year low of $1.60 and a 1-year high of $5.13.

This aggressive, young lithium miners vast new discovery wont stay a secret much longer and the growing, lithium supply shortage is a big opportunity for early investors.

Antares Pharma (NASDAQ:ATRS) last announced its quarterly earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $33.08 million for the quarter, compared to analyst estimates of $30.50 million. Antares Pharma had a return on equity of 2.38% and a net margin of 0.86%. As a group, sell-side analysts anticipate that Antares Pharma will post 0.02 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of ATRS. Amundi Pioneer Asset Management Inc. acquired a new stake in Antares Pharma during the 1st quarter worth about $730,000. Victory Capital Management Inc. boosted its position in shares of Antares Pharma by 28.6% during the 4th quarter. Victory Capital Management Inc. now owns 33,510 shares of the specialty pharmaceutical company's stock worth $157,000 after purchasing an additional 7,449 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Antares Pharma by 43.9% during the 4th quarter. Bank of Montreal Can now owns 20,426 shares of the specialty pharmaceutical company's stock worth $96,000 after purchasing an additional 6,236 shares in the last quarter. Barclays PLC boosted its position in shares of Antares Pharma by 90.7% during the 4th quarter. Barclays PLC now owns 190,986 shares of the specialty pharmaceutical company's stock worth $897,000 after purchasing an additional 90,830 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in shares of Antares Pharma by 18.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 62,167 shares of the specialty pharmaceutical company's stock worth $292,000 after purchasing an additional 9,689 shares in the last quarter. Hedge funds and other institutional investors own 40.27% of the company's stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: Why is the Consumer Price Index (CPI) important?

Get a free copy of the Zacks research report on Antares Pharma (ATRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [emailprotected]

7 Virus-Resistant Retail Stocks to Own Now

The U.S. economy contracted by 5% in the first quarter. That was slightly larger than the 4.8 decline that was previously forecast. On the same day that GDP was released, we also learned that the ranks of those filing for unemployment claims exceeded 40 million.

But as sobering as those numbers are, theyre not completely surprising. The U.S. economy was effectively shut down as citizens did their part to slow the spread of the novel coronavirus. But the cost of those efforts is just being measured.

And one of those measurements comes in the all-important Consumer Confidence Index. The index ticked up slightly in May to 86.6. While this number is about 30% lower than where the index sat In February, its significantly higher than where it sat at the trough of the financial crisis and subsequent recession.

And a big reason for that is that while the brick-and-mortar economy shut down, the digital economy helped give the economy a pulse.

Consumption is a key part of our economy. Thats why consumer confidence makes up 70% of the U.S. economy. And one of the key ways that consumers express that confidence or lack thereof, is in the retail sector.

For the last few years, the story of retail has been about which retailers were going to be able to successfully compete in the e-commerce space that is still owned by Amazon (NASDAQ:AMZN). Sadly, were discovering that some companies, like J.C. Penney, were late to adapt in a meaningful way. But that isnt the case for all retailers.

In this special presentation, we are identifying 7 retail stocks that have done well through this turbulent time and should use that as a springboard to continued growth.

View the "7 Virus-Resistant Retail Stocks to Own Now".

Read the original here:
Antares Pharma (NASDAQ:ATRS) Rating Increased to Hold at Zacks Investment Research - MarketBeat